Protein expression profiles in pancreatic adenocarcinoma compared with normal pancreatic tissue and tissue affected by pancreatitis as detected by two-dimensional gel electrophoresis and mass spectrometry

Cancer Research

Volumn 64, Issue 24, 2004, Pages 9018-9026

  Shen, Jianjun ^a   Person, Maria D ^b   Zhu, Jijiang ^c   Abbruzzese, James L ^c   Li, Donghui ^c  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ENOLASE; AMYLASE; ANNEXIN; CALCIUM BINDING PROTEIN; CALGRANULIN; CATHEPSIN D; CHAPERONE; COPPER ZINC SUPEROXIDE DISMUTASE; CYCLOPHILIN A; ENOLASE; GALECTIN 1; LIPOCORTIN 4; PEROXIREDOXIN; PEROXIREDOXIN I; PROTEIN 14 3 3; PROTEIN 14 3 3ZETA; PROTEIN DISULFIDE ISOMERASE; PROTEINASE; SCLEROPROTEIN; TROPOMYOSIN; TROPOMYOSIN 2; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; EARLY DIAGNOSIS; FATALITY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MASS SPECTROMETRY; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREATITIS; PH; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; TWO DIMENSIONAL GEL ELECTROPHORESIS; WESTERN BLOTTING;

BLOTTING, WESTERN; CARCINOMA, PANCREATIC DUCTAL; CHRONIC DISEASE; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HUMANS; IMMUNOHISTOCHEMISTRY; MASS SPECTROMETRY; NEOPLASM PROTEINS; PANCREATIC NEOPLASMS; PANCREATITIS; PROTEIN ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 10844252383     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-3262     Document Type: Article

References (50)

1. Friess H, Ding J, Kleeff J, et al. Microarray-based identification of differentially expressed growth- and metastasis-associated genes in pancreatic cancer. Cell Mol Life Sci 2003;60:1180-99.
2. Nakajima F, Nishimori H, Hata F, et al. Gene expression screening using a cDNA macroarray to clarify the mechanisms of peritoneal dissemination of pancreatic cancer. Surg Today 2003;33:190-5.
3. Iacobuzio-Donahue CA, Ashfaq R, Maitra A, et al. Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res 2003;63:8614-22.
4. Han H, Bearss DJ, Browne LW, et al. Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. Cancer Res 2002;62:2890-6.
5. Crnogorac-Jurcevic T, Efthimiou E, Nielsen T, et al. Expression profiling of microdissected pancreatic adenocarcinomas. Oncogene 2002;21:4587-94.
6. Iacobuzio-Donahue CA, Maitra A, Shen-Ong G, et al. Discovery of novel tumor markers of pancreatic cancer using global gene expression technology. Am J Pathol 2002;160:1239-49.
7. Logsdon CD, Simeohe DM, Binkley C, et al. Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res 2003;63:2649-57.
8. Shekouh AR, Thompson CC, Prime W, et al. Application of laser capture microdissection combined with two-dimensional electrophoresis for the discovery of differentially regulated proteins in pancreatic ductal adenocarcinoma. Proteomics 2003;3:1988-2001.
9. Shi T, Dong F, Liou LS, et al. Differential protein profiling in renal-cell carcinoma. Mol Carcinog 2004;40:47-61.
10. Tomonaga T, Matsushita K, Yamaguchi S, et al. Identification of altered protein expression and post-translational modifications in primary colorectal cancer by using agarose two-dimensional gel electrophoresis. Clin Cancer Res 2004;10:2007-14.
11. Roberts K, Bhatia K, Stanton P, Lord R. Proteomic analysis of selected prognostic factors of breast cancer. Proteomics 2004;4:784-92.
12. Zeindl-Eberhart E, Haraida S, Liebmann S, et al. Detection and identification of tumor-associated protein variants in human hepatocellular carcinomas. Hepatology 2004;39:540-9.
13. DiGiovanni J, Bol DK, Wilker E, et al. Constitutive expression of insulin-like growth factor-1 in epidermal basal cells of transgenic mice leads to spontaneous tumor promotion. Cancer Res 2000;60:1561-70.
14. Liu J, Shen JJ, Tanzillo-Swarts A, et al. Annexin II expression is reduced or lost in prostate cancer cells and its re-expression inhibits prostate cancer cell migration. Oncogene 2003;22:1475-85.
15. Rosenfeld J, Capdevielle J, Guillemot JC, et al. In-gel digestion of proteins for internal sequence analysis after one- or two-dimensional gel electrophoresis. Anal Biochem 1992;203:173-9.
16. Person MD, Lo HH, Towndrow KM, et al. Comparative identification of prostanoid inducible proteins by LC-ESI-MS/MS and MALDI-TOF mass spectrometry. Chem Res Toxicol 2003;16:757-7.
17. Jia Z, Person MD, Dong J, et al. Grp78 is essential for 11-deoxy,16,16-dimethyl PGE2-mediated cytoprotection in renal epithelial cells. Am J Physiol Renal Physiol 2004;287:F1113-22.
18. Clauser KR, Baker P, Burlingame AL, et al. Role of accurate mass measurement (+/- 10 ppm) in protein identification strategies employing MS or MS/MS and database searching. Anal Chem 1999;71:2871-82.
19. Berberat PO, Friess H, Wang L, et al. Comparative analysis of galectins in primary tumors and tumor metastasis in human pancreatic cancer. J Histochem Cytochem 2001;49:539-49.
20. Hede K. Environmental protection: studies highlight importance of tumor microenvironment. J Natl Cancer Inst 2004;96:1120-1.
21. Sausville EA. The challenge of pathway and environment-mediated drug resistance. Cancer Metastasis Rev 2001;20:117-22.
22. Paz A, Haklai R, Elad-Sfadia G, et al. Galectin-1 binds oncogenic H-Ras to mediate Ras membrane anchorage and cell transformation. Oncogene 2001;20:7486-93.
23. Elad-Sfadia G, Haklai R, Ballan E, et al. Galectin-1 augments Ras activation and diverts Ras signals to Raf-1 at the expense of phosphoinositide 3-kinase. J Biol Chem 2002;277:37169-75.
24. Pawlak G, Helfman DM. Cytoskeletal changes in cell transformation and tumorigenesis. Curr Opin Genet Dev 2001;11:41-7.
25. Mialhe A, Louis J, Pasquier D, et al. Expression of three cell adhesion molecules in bladder carcinomas: correlation with pathological features. Anal Cell Pathol 1997;13:125-36.
26. Pittenger MF, Kazzaz JA, Helfman DM. Functional properties of non-muscle tropomyosin isoforms. Curr Opin Cell Biol 1994;6:96-104.
27. Raval GN, Bharadwaj S, Levine EA, et al. Loss of expression of tropomyosin-1, a novel class II tumor suppressor that induces anoikis, in primary breast tumors. Oncogene 2003;22:6194-203.
28. Wang FL, Wang Y, Wong WK, et al. Two differentially expressed genes in normal human prostate tissue and in carcinoma. Cancer Res 1996;56:3634-7.
29. Jung MH, Kim SC, Jeon GA, et al. Identification of differentially expressed genes in normal and tumor human gastric tissue. Genomics 2000;69:281-6.
30. Pawlak G, McGarvey TW, Nguyen TB, et al. Alterations in tropomyosin isoform expression in human transitional cell carcinoma of the urinary bladder. Int J Cancer 2004;110:368-73.
31. Galloway PG, Likavec MJ, Perry G. Tropomyosin isoform expression in normal and neoplastic astrocytes. Lab Invest 1990;62:163-70.
32. Gimona M, Kazzaz J, Helfman DM. Forced expression of tropomyosin 2 or 3 in v-Ki-ras-transformed fibroblasts results in distinct phenotypic effects. Proc Natl Acad Sci USA 1996;93:9618-23.
33. Tada A, Kato H, Hasegawa S. Antagonistic effect of EGF against TGF β1 on transformed phenotype and tropomyosin expression of human lung carcinoma A549 cells. Oncol Rep 2000;7:1323-6.
34. Guan X, Juarez JC, Qi X, et al. Histidine-prolin-rich glycoprotein (HPRG) binds and transduces anti-angiogenic signals through cell surface tropomyosin on endothelial cells. Thromb Haemost 2004;92:403-12.
35. Zhang J, Gao FL, Zhi HY, et al. Expression patterns of esophageal cancer deregulated genes in C57BL/6J mouse embryogenesis. World J Gastroenterol 2004;10:1088-92.
36. Luo A, Kong J, Hu G, et al. Discovery of Ca2+-relevant and differentiation-associated genes downregulated in esophageal squamous cell carcinoma using cDNA microarray. Oncogene 2004;23:1291-9.
37. El-Rifai W, Moskaluk CA, Abdrabbo MK, et al. Gastric cancers overexpress S100A calcium-binding proteins. Cancer Res 2002;62:6823-6.
38. Zucchini C, Biolchi A, Strippoli P, et al. Expression profile of epidermal differentiation complex genes in normal and anal cancer cells. Int J Oncol 2001;19:1133-41.
39. Ott HW, Lindner H, Sarg B, et al. Calgranulins in cystic fluid and serum from patients with ovarian carcinomas. Cancer Res 2003;63:7507-14.
40. Sommer A, Hoffmann J, Lichtner RB, et al. Studies on the development of resistance to the pure antiestrogen Faslodex in three human breast cancer cell lines. J Steroid Biochem Mol Biol 2003;85:33-47.
41. Heizmann CW, Fritz G, Schafer BW. S100 proteins: structure, functions and pathology Front Biosci 2002;7:d1356-68.
42. Emberley ED, Murphy LC, Watson PH. S100 proteins and their influence on pro-survival pathways in cancer. Biochem Cell Biol 2004;82:508-15.
43. Schreiber SL. Chemistry and biology of the immunophilins and their immunosuppressive ligands. Science 1991;251:283-7.
44. Brazin KN, Mallis RJ, Fulton DB, et al. Regulation of the tyrosine kinase ltk by the peptidyl-prolyl isomerase cyclophilin A. Proc Natl Acad Sci USA 2002;99:1899-904.
45. Campa MJ, Wang MZ, Howard B, et al. Protein expression profiling identifies macrophage migration inhibitory factor and cyclophilin a as potential molecular targets in non-small cell lung cancer. Cancer Res 2003;63:1652-6.
46. Key O, Baluda MA, Park NH. Differential gene expression in neoplastic and human papillomavirus-immortalized oral keratinocytes. Oncogene 1999;18:827-31.
47. Yaffe MB, Rittinger K, Volinia S, et al. The structural basis for 14-3-3:phosphopeptide binding specificity. Cell 1997;91:961-71.
48. Clark GJ, Drugan JK, Rossman KL, et al. 14-3-3 ζ negatively regulates raf-1 activity by interactions with the Raf-1 cysteine-rich domain. J Biol Chem 1997;272:20990-3.
49. Rommel C, Radziwill G, Lovric J, et al. Activated Ras displaces 14-3-3 protein from the amino terminus of c-Raf-1. Oncogene 1996;12:609-19.
50. Pike SE, Yao L, Setsuda J, et al. Calreticulin and calreticulin fragments are endothelial cell inhibitors that suppress tumor growth. Blood 1999;94:2461-8.